ArticleAmerican journal of hematology2009
Generation and phenotyping of mCd59a and mCd59b double-knockout mice.
Article in American journal of hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 28 citations in OpenAlex.
- Glycated CD59: a novel biomarker for gestational diabetes.Endocrine reviews · 2026Review
- Friend or foe: assessing the value of animal models for facilitating clinical breakthroughs in complement research.The Journal of clinical investigation · 2025Review
- HnRNPM modulates alternative splicing in germ cells by recruiting PTBP1.Reproductive biology and endocrinology : RB&E · 2025Article
- Complement or insult: the emerging link between complement cascade deficiencies and pathology of myeloid malignancies.Journal of leukocyte biology · 2024Review
- Enhanced complement activation and MAC formation accelerates severe COVID-19.Cellular and molecular life sciences : CMLS · 2024Article
- Emerging role of complement in COVID-19 and other respiratory virus diseases.Cellular and molecular life sciences : CMLS · 2024Review
- CD59-Regulated Ras Compartmentalization Orchestrates Antitumor T-cell Immunity.Cancer immunology research · 2022Article
- Versatile cell ablation tools and their applications to study loss of cell functions.Cellular and molecular life sciences : CMLS · 2019Review
- Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice.Journal of diabetes and its complications · 2017Article
- Target deletion of complement component 9 attenuates antibody-mediated hemolysis and lipopolysaccharide (LPS)-induced acute shock in mice.Scientific reports · 2016Article
- Role of complement and complement regulatory proteins in the complications of diabetes.Endocrine reviews · 2015Review
- Targeting therapy to the neuromuscular junction: proof of concept.Muscle & nerve · 2014Article
- Complement and HIV-I infection/HIV-associated neurocognitive disorders.Journal of neurovirology · 2014Review
- CD59 underlines the antiatherosclerotic effects of C-phycocyanin on mice.BioMed research international · 2013Article
- Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity.Current pharmaceutical design · 2012Article
- The protective role of CD59 and pathogenic role of complement in hepatic ischemia and reperfusion injury.The American journal of pathology · 2011Article
- Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.Cancer research · 2011Article
- Soluble CD59 expressed from an adenovirus in vivo is a potent inhibitor of complement deposition on murine liver vascular endothelium.PloS one · 2011Article
- Genome-wide identification of TAL1's functional targets: insights into its mechanisms of action in primary erythroid cells.Genome research · 2010Article
- Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice.Circulation · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
CD59 is a membrane protein inhibitor of the membrane attack complex (MAC) of complement. Humans express only one, whereas mice express two CD59 genes. We previously reported the targeted deletion of the mCd59b gene in which absence of mCd59b together with an unintended down regulation of mCd59a caused hemolytic anemia with spontaneous platelet activation. To confirm the complement role in the hemolytic anemia caused by abrogation of mCd59 function, we have developed a mCd59a and mCd59b double knock out mice and analyzed its phenotype in complement sufficient and deficient (C3(-/-)). We report here that total abrogation of mCd59 function in mCd59ab(-/-) mice results in complement-mediated hemolytic anemia that is rescued by the deficiency of C3 in compound mCd59ab(-/-)/C3(-/-) mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.